Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
AstraZeneca Bristol-Myers Squibb |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00688493 |
The main purpose of this study is to examine the effect of dapagliflozin on electronic measures of heart beats in healthy males
Condition | Intervention | Phase |
---|---|---|
Healthy |
Drug: Dapagliflozin Drug: Moxifloxacin Drug: Placebo to match moxifloxacin and dapagliflozin |
Phase I |
Study Type: | Interventional |
Study Design: | Basic Science, Randomized, Double Blind (Subject, Investigator), Crossover Assignment, Pharmacokinetics/Dynamics Study |
Official Title: | A Double-Blind, Randomized, Four-Period Crossover Study to Assess the Effects of Single Oral Dose Dapagliflozin Administration on QTc Interval Compared to Placebo, Using AVELOX™ (Moxifloxacin) as a Positive Control, in Healthy Male Volunteers Age 18 to 45 Years |
Enrollment: | 36 |
Study Start Date: | July 2007 |
Study Completion Date: | May 2008 |
Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
20 mg single dose of dapagliflozin: Experimental
20 mg dapagliflozin
|
Drug: Dapagliflozin
3 x 50 mg tablets, single oral dose
Drug: Dapagliflozin
2 x 10 mg capsules, single oral dose
Drug: Moxifloxacin
Overencapsulated 400 mg capsule, single oral dose
Drug: Placebo to match moxifloxacin and dapagliflozin
Overencapsulated 400 mg capsule, single oral dose
|
150 mg single dose of dapagliflozin2: Experimental
150 mg dapagliflozin
|
Drug: Dapagliflozin
3 x 50 mg tablets, single oral dose
Drug: Dapagliflozin
2 x 10 mg capsules, single oral dose
Drug: Moxifloxacin
Overencapsulated 400 mg capsule, single oral dose
Drug: Placebo to match moxifloxacin and dapagliflozin
Overencapsulated 400 mg capsule, single oral dose
|
400 mg single dose of moxifloxacin: Active Comparator
Moxifloxacin
|
Drug: Dapagliflozin
3 x 50 mg tablets, single oral dose
Drug: Dapagliflozin
2 x 10 mg capsules, single oral dose
Drug: Moxifloxacin
Overencapsulated 400 mg capsule, single oral dose
Drug: Placebo to match moxifloxacin and dapagliflozin
Overencapsulated 400 mg capsule, single oral dose
|
Placebo: Placebo Comparator
Placebo
|
Drug: Dapagliflozin
3 x 50 mg tablets, single oral dose
Drug: Dapagliflozin
2 x 10 mg capsules, single oral dose
Drug: Moxifloxacin
Overencapsulated 400 mg capsule, single oral dose
Drug: Placebo to match moxifloxacin and dapagliflozin
Overencapsulated 400 mg capsule, single oral dose
|
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Maryland | |
Research Site | |
Baltimore, Maryland, United States |
Study Director: | Glenn Carlson, MD | AstraZeneca |
Principal Investigator: | Ronald Goldwater, MD | Parexel International |
Responsible Party: | AstraZeneca Pharmaceuticals ( Shamik Parikh, MD, Medical Science Director, Dapagliflozin ) |
Study ID Numbers: | D1690C00001 |
Study First Received: | May 30, 2008 |
Last Updated: | June 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00688493 |
Health Authority: | United States: Food and Drug Administration |
QT Healthy volunteers |
Moxifloxacin Healthy |
Anti-Infective Agents Therapeutic Uses Pharmacologic Actions |